2 Big Risks and 2 Big Opportunities for Ginkgo Bioworks Stock
Ginkgo Bioworks isn't yet profitable, so it's running on a finite amount of cash. Cutting expenses may actually cause the company to lose out on revenue.
This 1 AI Stock Could Revolutionize Biotech and Pharma
Ginkgo Bioworks seeks to create a high-throughput biopharma services platform. So far, that platform isn't profitable, but it can still generate a lot of scientific data.
Maravai LifeSciences' Cygnus & TriLink Unveil AccuRes DNA Kits
MRVI's Cygnus and TriLink introduce AccuRes kits, setting a new standard in host cell DNA quantification with unmatched sensitivity and specificity.
From Promise to Peril: The Downfall of Ginkgo Bioworks
“Our revenue has grown substantially, and we are proud of the progress we've made in establishing strategic partnerships. The robust pipeline of projects we have in place positions us well for continued financial success.
Down 88% in 1 Year, What's Next for Ginkgo Bioworks Stock?
Ginkgo Bioworks is still not anywhere close to being operationally profitable. Management isn't planning on it becoming profitable anytime soon.
Why Is Diagnostic Tests Provider Applied DNA Sciences Stock Trading Higher On Friday?
Applied DNA Sciences, Inc. APDN stock traded higher on Friday on a strong session volume of 114.23 million, compared to the average volume of 6.78 million, according to data from Benzinga Pro.
Applied DNA Submits Validation Package to New York State Department of Health to Expand Linea Mpox Virus 1.0 Assay to Mpox Clade I
-Validation Studies Confirmed the Assay Can Detect Mpox Clade I and Clade Ib in addition to Clade II- STONY BROOK, NY / ACCESSWIRE / August 23, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in PCR-based DNA technologies, today announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has submitted a validation package to the New York State Department of Health (NYSDOH) in support of an expansion of the permitted use of its Linea™ Mpox Virus 1.0 Assay (the "Assay") to include both mpox clade I and clade II. The Company's validation studies concluded that the Assay's primers and probe have 100% homology to mpox clade I and clade Ib, the latter of which was the subject of the World Health Organization's (WHO) recently declared public health emergency of international concern.
Ginkgo Bioworks: Here Comes The Test
Ginkgo Bioworks has struggled with missed revenue targets, leading to a significant decline in share value. The recent Q2 report showed a 30% decrease in total revenues, with cost structure still a major issue for the company. Balance sheet weakening as cash reserves decrease, putting pressure on working capital and financial flexibility.
Applied DNA To Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I
STONY BROOK, NY / ACCESSWIRE / August 19, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its intention to seek an expansion of the approved intended use of its Linea™ Mpox Virus 1.0 Assay (the "Assay") to include the detection of mpox Clade I that is the subject of the World Health Organization's (WHO) 14 August 2024 declaration of a public health emergency of international concern (PHEIC). The Company's internally generated data show that the Assay can detect the genetic sequence of mpox Clade I and is now undertaking validation studies to enable the filing of necessary documentation with the New York State Department of Health (NYSDOH).
Down 86% This Year, Is Ginkgo Bioworks Stock a Bargain Now?
Ginkgo Bioworks' market cap has plummeted from more than $25 billion at its peak to less than $600 million at recent prices. The company has announced heaps of layoffs this year in response to heavy losses.
Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks
AI holds tremendous promise for the biopharma industry. Using AI to identify candidates for new drugs is already happening.
Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results
- Conference Call/Webcast Scheduled for Today at 4:30 PM ET - STONY BROOK, NY / ACCESSWIRE / August 8, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for its third fiscal quarter ended June 30, 2024. The Company's Form 10-Q can be viewed at Click Here
